Advocacy intelligence hub — real-time data for patient organizations
Thalomid: FDA approved
Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Thalomid
(Thalidomide)Orphan drugCelgene Corporation
12.1 Mechanism of Action The mechanism of action of THALOMID is not fully understood. Cellular activities of thalidomide are mediated through its targ...
Douglas S Hawkins
Children's Oncology Group
📍 Birmingham, Alabama
Tri A. Dinh, MD
Mayo Clinic
Julia Glade-Bender
Children's Oncology Group
Peter ODwyer
Abramson Cancer Center at Penn Medicine
Trent Hummel, M.D
COG Phase I Consortium
📍 CINCINNATI, OH
Patrick A. Thompson, MD
Baylor College of Medicine
View all Teratoma of the central nervous system specialists →